Keyword: Impax Laboratories

Justice Department building inscription

DOJ charges likely to hit only a few generics makers: Analysts

Generics makers lost $8.5 billion in value Thursday on news that the feds are prepping price-fixing charges against industry players. The good news: Though the danger is real--and quite significant--analysts figure it will be confined to only a few of the 12 companies that have received federal subpoenas.
Mylan's EpiPen

Mylan may get the 'horns' from EpiPen competitors

Some analysts think Mylan may not escape lasting impact from the EpiPen pricing controversy. The way they see it, the FDA is under intense pressure to approve competing products--Teva’s for one--and other players like Impax Laboratories are positioning themselves to snatch away market share.